Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 536

1.

Matrix stiffness regulates endosomal escape of uropathogenic E. coli.

Moorthy S, Byfield FJ, Janmey PA, Klein EA.

Cell Microbiol. 2020 Feb 21:e13196. doi: 10.1111/cmi.13196. [Epub ahead of print]

PMID:
32083802
2.

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.

Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N.

Ann Oncol. 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11.

PMID:
32057540
3.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W.

Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491.

4.

A Transcriptome-Wide Association Study (TWAS) Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.

Zhong J, Jermusyk A, Wu L, Hoskins JW, Collins I, Mocci E, Zhang M, Song L, Chung CC, Zhang T, Xiao W, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt S, Borgida A, Bracci PM, Brais L, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Childs EJ, Cotterchio M, Du M, Duell EJ, Fuchs C, Gallinger S, Gaziano JM, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Haiman C, Hartge P, Hasan M, Helzlsouer KJ, Holly EA, Klein EA, Kogevinas M, Kurtz RJ, LeMarchand L, Malats N, Männistö S, Milne R, Neale RE, Ng K, Obazee O, Oberg AL, Orlow I, Patel AV, Peters U, Porta M, Rothman N, Scelo G, Sesso HD, Severi G, Sieri S, Silverman D, Sund M, Tjønneland A, Thornquist MD, Tobias GS, Trichopoulou A, Van Den Eeden SK, Visvanathan K, Wactawski-Wende J, Wentzensen N, White E, Yu H, Yuan C, Zeleniuch-Jacquotte A, Hoover R, Brown K, Kooperberg C, Risch HA, Jacobs EJ, Li D, Yu K, Shu XO, Chanock SJ, Wolpin BM, Stolzenberg-Solomon RZ, Chatterjee N, Klein AP, Smith JP, Kraft P, Shi J, Petersen GM, Zheng W, Amundadottir LT.

J Natl Cancer Inst. 2020 Jan 9. pii: djz246. doi: 10.1093/jnci/djz246. [Epub ahead of print]

PMID:
31917448
5.

Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment.

Falzarano SM, Nyame YA, McKenney JK, Przybycin CG, Li J, Stephenson A, Fergany A, Zhou M, Klein EA, Magi-Galluzzi C.

Prostate Cancer Prostatic Dis. 2020 Jan 3. doi: 10.1038/s41391-019-0199-1. [Epub ahead of print]

PMID:
31900431
6.

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.

Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H.

J Clin Oncol. 2019 Dec 12:JCO1902768. doi: 10.1200/JCO.19.02768. [Epub ahead of print]

PMID:
31829902
7.

Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.

Tom MC, Reddy CA, Smile TD, Zhang RX, Ciezki JP, Stephans KL, Mian OY, Klein EA, Campbell S, Ulchaker J, Angermeier K, Tendulkar RD.

Brachytherapy. 2020 Jan - Feb;19(1):43-50. doi: 10.1016/j.brachy.2019.10.005. Epub 2019 Dec 5.

PMID:
31813740
8.

The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy.

DeWitt-Foy ME, Klein EA, ElShafei A, Coronado WM, Campbell S, Gong M, Berglund R, Ulchaker J, Fareed K, Abouassaly R.

Urology. 2020 Mar;137:115-120. doi: 10.1016/j.urology.2019.11.018. Epub 2019 Nov 27.

PMID:
31785277
9.

Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.

Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, Leverson G, Woo K, Sonn GA, Klein EA, Fumo M, Huang W, Jarrard DF.

Clin Epigenetics. 2019 Nov 28;11(1):168. doi: 10.1186/s13148-019-0771-5.

10.

Sugar-Phosphate Metabolism Regulates Stationary-Phase Entry and Stalk Elongation in Caulobacter crescentus.

de Young KD, Stankeviciute G, Klein EA.

J Bacteriol. 2020 Jan 29;202(4). pii: e00468-19. doi: 10.1128/JB.00468-19. Print 2020 Jan 29.

PMID:
31767777
11.

Reply by Authors.

Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK.

J Urol. 2020 Feb;203(2):318-319. doi: 10.1097/01.JU.0000612400.91383.e8. Epub 2019 Oct 30. No abstract available.

PMID:
31664885
12.

Rapid and structure-specific cellular uptake of selected steroids.

McManus JM, Bohn K, Alyamani M, Chung YM, Klein EA, Sharifi N.

PLoS One. 2019 Oct 17;14(10):e0224081. doi: 10.1371/journal.pone.0224081. eCollection 2019.

13.

L-3,3',5-triiodothyronine and pregnenolone sulfate inhibit Torpedo nicotinic acetylcholine receptors.

Moffett SX, Klein EA, Brannigan G, Martin JV.

PLoS One. 2019 Oct 4;14(10):e0223272. doi: 10.1371/journal.pone.0223272. eCollection 2019.

14.

Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.

Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK.

J Urol. 2020 Feb;203(2):311-319. doi: 10.1097/JU.0000000000000526. Epub 2019 Sep 4.

PMID:
31483693
15.

Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.

Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2020 Mar;23(1):136-143. doi: 10.1038/s41391-019-0167-9. Epub 2019 Aug 27.

PMID:
31455846
16.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Barzi A, Lara PN Jr, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S.

Cancer. 2019 Nov 1;125(21):3853-3863. doi: 10.1002/cncr.32290. Epub 2019 Aug 9.

PMID:
31398279
17.

Reply by Authors.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 Nov;202(5):958. doi: 10.1097/01.JU.0000579312.61159.39. Epub 2019 Oct 9. No abstract available.

PMID:
31364932
18.

Impact of using 29 MHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience.

Abouassaly R, Klein EA, El-Shefai A, Stephenson A.

World J Urol. 2019 Jul 15. doi: 10.1007/s00345-019-02863-y. [Epub ahead of print]

PMID:
31309290
19.

Editorial Comment.

Klein EA.

J Urol. 2019 Oct;202(4):701. doi: 10.1097/01.JU.0000576692.80637.d0. Epub 2019 Sep 6. No abstract available.

PMID:
31268814
20.

Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.

Barata PC, Magi-Galluzzi C, Gupta R, Dreicer R, Klein EA, Garcia JA.

Clin Genitourin Cancer. 2019 Oct;17(5):366-372. doi: 10.1016/j.clgc.2019.05.021. Epub 2019 May 25.

PMID:
31262501
21.

SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.

Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC.

J Urol. 2019 Nov;202(5):952-958. doi: 10.1097/JU.0000000000000357. Epub 2019 Oct 9.

PMID:
31144591
22.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
23.

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.

Mossanen M, Nepple KG, Grubb RL 3rd, Androile GL, Kallogjeri D, Klein EA, Stephenson AJ, Kibel AS.

Eur Urol Oncol. 2018 Jun;1(2):143-148. doi: 10.1016/j.euo.2018.02.004. Epub 2018 May 15.

PMID:
31100238
24.

Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance.

Dai C, Ganesan V, Nyame YA, Almassi N, Greene DJ, Hettel D, Magi-Galluzzi C, Gong M, Jones JS, Stephenson AJ, Berglund RK, Klein EA.

Urology. 2019 Aug;130:106-112. doi: 10.1016/j.urology.2019.02.050. Epub 2019 May 7.

PMID:
31071349
25.

Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.

Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA.

Invest New Drugs. 2019 Jun;37(3):559-566. doi: 10.1007/s10637-019-00778-4. Epub 2019 Apr 30.

PMID:
31037562
26.

Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.

Nyame YA, Wilkins L, Greene DJ, Ganesan V, Dai C, Almassi N, Stephenson AJ, Gong M, Berglund R, Klein EA.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):617-623. doi: 10.1038/s41391-019-0147-0. Epub 2019 Apr 17.

PMID:
30996285
27.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2020 Jan;77(1):3-10. doi: 10.1016/j.eururo.2019.03.022. Epub 2019 Apr 13.

PMID:
30992160
28.

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Apr 4;14(4):e0215108. doi: 10.1371/journal.pone.0215108. eCollection 2019.

29.

Caulobacter crescentus Adapts to Phosphate Starvation by Synthesizing Anionic Glycoglycerolipids and a Novel Glycosphingolipid.

Stankeviciute G, Guan Z, Goldfine H, Klein EA.

mBio. 2019 Apr 2;10(2). pii: e00107-19. doi: 10.1128/mBio.00107-19.

30.

A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy.

Bryk DJ, Angermeier KW, Klein EA.

Urology. 2019 Jul;129:e4-e5. doi: 10.1016/j.urology.2019.03.022. Epub 2019 Mar 30.

PMID:
30935936
31.

Editorial Comment.

Klein EA.

J Urol. 2019 Jul;202(1):101. doi: 10.1097/01.JU.0000557776.45657.c9. Epub 2019 Jun 7. No abstract available.

PMID:
30933553
32.

Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.

Purysko AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, Davicioni E, du Plessis M, Buerki C, Bullen J, Li L, Madabhushi A, Stephenson A, Klein EA.

Eur Radiol. 2019 Sep;29(9):4861-4870. doi: 10.1007/s00330-019-06114-x. Epub 2019 Mar 7.

33.

Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Mar 1;14(3):e0213209. doi: 10.1371/journal.pone.0213209. eCollection 2019. Erratum in: PLoS One. 2019 Apr 4;14(4):e0215108.

34.

Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.

Stovsky M, Klein EA, Chait A, Manickam K, Stephenson AJ, Wagner M, Dineen M, Lotan Y, Partin A, Baniel J, Kestranek A, Gawande P, Boris Zaslavsky.

J Urol. 2019 Jun;201(6):1115-1120. doi: 10.1097/JU.0000000000000185.

PMID:
30810464
35.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

36.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

37.

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF.

BJU Int. 2019 Aug;124(2):282-289. doi: 10.1111/bju.14671. Epub 2019 Feb 10.

PMID:
30653804
38.

Differential modes of crosslinking establish spatially distinct regions of peptidoglycan in Caulobacter crescentus.

Stankeviciute G, Miguel AV, Radkov A, Chou S, Huang KC, Klein EA.

Mol Microbiol. 2019 Apr;111(4):995-1008. doi: 10.1111/mmi.14199. Epub 2019 Feb 3.

PMID:
30614079
39.

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):399-405. doi: 10.1038/s41391-018-0101-6. Epub 2018 Dec 12.

40.

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer.

Walsh N, Zhang H, Hyland PL, Yang Q, Mocci E, Zhang M, Childs EJ, Collins I, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Canzian F, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman GE, Goodman PJ, Hung RJ, Kooperberg C, Kurtz RC, Malats N, LeMarchand L, Neale RE, Olson SH, Scelo G, Shu XO, Van Den Eeden SK, Visvanathan K, White E, Zheng W; PanScan and PanC4 consortia, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Borgida A, Boutron-Ruault MC, Brais L, Brennan P, Bueno-de-Mesquita B, Buring J, Chaffee KG, Chanock S, Cleary S, Cotterchio M, Foretova L, Fuchs C, M Gaziano JM, Giovannucci E, Goggins M, Hackert T, Haiman C, Hartge P, Hasan M, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Janout V, Klein EA, Kurtz RC, Laheru D, Lee IM, Lu L, Malats N, Mannisto S, Milne RL, Oberg AL, Orlow I, Patel AV, Peters U, Porta M, Real FX, Rothman N, Sesso HD, Severi G, Silverman D, Strobel O, Sund M, Thornquist MD, Tobias GS, Wactawski-Wende J, Wareham N, Weiderpass E, Wentzensen N, Wheeler W, Yu H, Zeleniuch-Jacquotte A, Kraft P, Li D, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Amundadottir LT, Yu K, Klein AP, Stolzenberg-Solomon RZ.

J Natl Cancer Inst. 2019 Jun 1;111(6):557-567. doi: 10.1093/jnci/djy155.

41.

Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.

Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF.

Cancer. 2019 Feb 1;125(3):391-397. doi: 10.1002/cncr.31833. Epub 2018 Nov 13.

42.

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.

43.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

44.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
45.
46.

Perioperative Troponin is a Predictor of Both Short- and Intermediate-term Mortality Among Patients Undergoing Major Urologic Surgery.

Nyame YA, Abelson B, Khanna A, Menon V, Klein EA, Goldman HB.

Urology. 2019 Jan;123:108-113. doi: 10.1016/j.urology.2018.06.060. Epub 2018 Sep 7.

PMID:
30201299
47.

The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.

Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T, Knezevic D, Febbo PG, Lawrence J, Klein EA.

Urology. 2018 Nov;121:132-138. doi: 10.1016/j.urology.2018.07.018. Epub 2018 Aug 22.

48.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

49.

IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer.

Tang W, Wallace TA, Yi M, Magi-Galluzzi C, Dorsey TH, Onabajo OO, Obajemu A, Jordan SV, Loffredo CA, Stephens RM, Silverman RH, Stark GR, Klein EA, Prokunina-Olsson L, Ambs S.

Clin Cancer Res. 2018 Nov 1;24(21):5471-5481. doi: 10.1158/1078-0432.CCR-18-1060. Epub 2018 Jul 16.

50.

Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care.

Misra-Hebert AD, Hom G, Klein EA, Bauman JM, Gupta N, Ji X, Stephenson AJ, Jones JS, Kattan MW.

Front Oncol. 2018 Jun 28;8:238. doi: 10.3389/fonc.2018.00238. eCollection 2018.

Supplemental Content

Loading ...
Support Center